BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Diabetic Peripheral Neuropathic Pain readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Diabetic Peripheral N
 europathic Pain\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06696443-8794@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20270125
DTEND;VALUE=DATE:20270126
SUMMARY:Journavx (Suzetrigine): Phase 3 readout est. (NCT06696443)
DESCRIPTION:Journavx (Suzetrigine)\, phase 3\, Diabetic Peripheral Neuropat
 hic Pain.\nStudy: Evaluation of the Long-term Safety and Effectiveness of 
 Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropa
 thy (DPN)\nEstimated primary completion: 25 January 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/suzetrigine#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06696443
URL:https://assetmemo.bio/drug/suzetrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06619860-8820@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20270325
DTEND;VALUE=DATE:20270326
SUMMARY:VX-993: Phase 2 readout est. (NCT06619860)
DESCRIPTION:VX-993\, phase 2\, Diabetic Peripheral Neuropathic Pain.\nStudy
 : Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Dia
 betic Peripheral Neuropathy\nEstimated primary completion: 25 March 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/vx-993#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06619860
URL:https://assetmemo.bio/drug/vx-993#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05986292-8814@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:LY4065967: Phase 2 readout est. (NCT05986292)
DESCRIPTION:LY4065967\, phase 2\, Diabetic Peripheral Neuropathic Pain.\nSt
 udy: A Master Protocol Study (LY900028) of Multiple Intervention-Specific-
 Appendices (ISAs) in Participants With Chronic Pain\nEstimated primary com
 pletion: April 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 ly4065967#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT05986292
URL:https://assetmemo.bio/drug/ly4065967#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07231419-8794@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20270406
DTEND;VALUE=DATE:20270407
SUMMARY:Journavx (Suzetrigine): Phase 3 readout est. (NCT07231419)
DESCRIPTION:Journavx (Suzetrigine)\, phase 3\, Diabetic Peripheral Neuropat
 hic Pain.\nStudy: Evaluation of Efficacy and Safety of Suzetrigine (SUZ) f
 or Pain Associated With Diabetic Peripheral Neuropathy\nEstimated primary 
 completion: 6 April 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/suzetrigine#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07231419
URL:https://assetmemo.bio/drug/suzetrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06628908-8794@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Journavx (Suzetrigine): Phase 3 readout est. (NCT06628908)
DESCRIPTION:Journavx (Suzetrigine)\, phase 3\, Diabetic Peripheral Neuropat
 hic Pain.\nStudy: Evaluation of Efficacy and Safety of Suzetrigine for Pai
 n Associated With Diabetic Peripheral Neuropathy\nEstimated primary comple
 tion: 31 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/su
 zetrigine#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06628908
URL:https://assetmemo.bio/drug/suzetrigine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07712913-4854@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Pregabalin: Phase 3 readout est. (NCT07712913)
DESCRIPTION:Pregabalin\, phase 3\, Diabetic Peripheral Neuropathic Pain.\nS
 tudy: Extended-release Pregabalin for the Treatment of Neuropathic Pain in
  Patients With Diabetic Peripheral Neuropathy and Postherpetic Neuralgia\n
 Estimated primary completion: 1 June 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/pregabalin#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07712913
URL:https://assetmemo.bio/drug/pregabalin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07285018-8814@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:LY4065967: Phase 2 readout est. (NCT07285018)
DESCRIPTION:LY4065967\, phase 2\, Diabetic Peripheral Neuropathic Pain.\nSt
 udy: A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Partic
 ipants With Diabetic Peripheral Neuropathic Pain\nEstimated primary comple
 tion: July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ly40
 65967#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07285018
URL:https://assetmemo.bio/drug/ly4065967#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06614322-4854@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Pregabalin: Phase 2 readout est. (NCT06614322)
DESCRIPTION:Pregabalin\, phase 2\, Diabetic Peripheral Neuropathic Pain.\nS
 tudy: SPENDD: Quantitative Sensory Testing and Analgesic Response for Pain
 ful Peripheral Neuropathy.\nEstimated primary completion: 1 June 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/pregabalin#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06614322
URL:https://assetmemo.bio/drug/pregabalin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06614322-7141@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Cymbalta (Duloxetine): Phase 2 readout est. (NCT06614322)
DESCRIPTION:Cymbalta (Duloxetine)\, phase 2\, Diabetic Peripheral Neuropath
 ic Pain.\nStudy: SPENDD: Quantitative Sensory Testing and Analgesic Respon
 se for Painful Peripheral Neuropathy.\nEstimated primary completion: 1 Jun
 e 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/duloxetine#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT066143
 22
URL:https://assetmemo.bio/drug/duloxetine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07859111-8791@assetmemo.bio
DTSTAMP:20261121T005010Z
DTSTART;VALUE=DATE:20280830
DTEND;VALUE=DATE:20280831
SUMMARY:Crisugabalin: Phase 3 readout est. (NCT07859111)
DESCRIPTION:Crisugabalin\, phase 3\, Diabetic Peripheral Neuropathic Pain.\
 nStudy: YJ001 Spray for Diabetic Peripheral Neuropathic Pain\nEstimated pr
 imary completion: 30 August 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/crisugabalin#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07859111
URL:https://assetmemo.bio/drug/crisugabalin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
